AZD4877
Phase 1Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myelogenous Leukemia
Conditions
Acute Myelogenous Leukemia
Trial Timeline
Jul 1, 2007 → Jul 1, 2009
NCT ID
NCT00486265About AZD4877
AZD4877 is a phase 1 stage product being developed by AstraZeneca for Acute Myelogenous Leukemia. The current trial status is terminated. This product is registered under clinical trial identifier NCT00486265. Target conditions include Acute Myelogenous Leukemia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00661609 | Phase 2 | Completed |
| NCT00613652 | Phase 1 | Completed |
| NCT00486265 | Phase 1 | Terminated |
| NCT00471367 | Phase 1 | Terminated |
| NCT00460460 | Phase 1 | Terminated |
| NCT00389389 | Phase 1 | Completed |
Competing Products
20 competing products in Acute Myelogenous Leukemia